相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
Filip Baert et al.
JOURNAL OF CROHNS & COLITIS (2013)
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review
Herma H. Fidder et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
E. Bultman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis
Lennard Y. W. Lee et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Adalimumab for Crohn's Disease in Clinical Practice at Mayo Clinic: The First 118 Patients
Jason M. Swoger et al.
INFLAMMATORY BOWEL DISEASES (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
A. Swaminath et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Long-term durability of Crohn's disease treatment with infliximab
Stephen J. Rudolph et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
The use of adalimumab in the management of refractory Crohn's disease
G. -T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
KA Papadakis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab treatment for Crohn's disease: One-year experience in a Dutch academic hospital
DW Hommes et al.
INFLAMMATORY BOWEL DISEASES (2002)
分享论文
